(Q58614572)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22473105%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

title

Molecular prescreening to select patient population in early clinical trials (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22473105%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22473105%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Ana Vivancos

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22473105%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Santiago Ramon y Cajal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22473105%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Josep Tabernero Caturla

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22473105%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

author name string

Jordi Rodón

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22473105%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Rodrigo Dienstmann

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22473105%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

José Baselga

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22473105%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

language of work or name

English

0 references

publication date

3 April 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22473105%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Clinical Oncology

27 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22473105%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22473105%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22473105%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

page(s)

359-366

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22473105%20AND%20SRC:MED&resulttype=core&format=json

Mapping copy number variation by population-scale genome sequencing

27 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Integrated genomic analyses of ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

International network of cancer genome projects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Risks and benefits of phase 1 oncology trials, 1991 through 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Trastuzumab--mechanism of action and use in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

21 January 2018

Cancer pharmacogenomics

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Envisioning the future of early anticancer drug development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

The Phase III Trial in the Era of Targeted Therapy: Unraveling the “Go or No Go” Decision

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

The PIK3CA gene is mutated with high frequency in human breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Clinical studies of histone deacetylase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Anti-VEGF therapy: the search for clinical biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Novel therapeutic targets in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Personalized treatment of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Project Zero Delay: a process for accelerating the activation of cancer clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Methods of molecular analysis: mutation detection in solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Genotyping technologies for genetic research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Cancer genomics: technology, discovery, and translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Quantifying EGFR alterations in the lung cancer genome with nanofluidic digital PCR arrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Genome remodelling in a basal-like breast cancer metastasis and xenograft

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Distant metastasis occurs late during the genetic evolution of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Human cancers express mutator phenotypes: origin, consequences and targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Microvesicles: messengers and mediators of tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Circulating tumor cells as pharmacodynamic biomarker in early clinical oncological trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Prognostic value of circulating mutant DNA in unresectable metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Detection of mutations in EGFR in circulating lung-cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Personalized oncology through integrative high-throughput sequencing: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Bevacizumab and recurrent malignant gliomas: a European perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

The BATTLE trial: personalizing therapy for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

The Catalogue of Somatic Mutations in Cancer (COSMIC)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

On telomere shortening in soft-tissue tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Targeted therapies: chemotherapy-free option for relapsed patients with breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Parallel anticancer drug development and molecular stratification to qualify predictive biomarkers: dealing with obstacles hindering progress

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

BATTLE to personalize lung cancer treatment. Novel clinical trial design and tissue gathering procedures drive biomarker discovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

WIN Consortium--challenges and advances

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.48

Tumor heterogeneity: causes and consequences

31 March 2020

1 reference

12 December 2020

p53 Mutation and MDM2 amplification in human soft tissue sarcomas

1 reference

12 December 2020

ERK1/2 phosphorylation: a biomarker analysis within a phase I study with the new Raf kinase inhibitor BAY43-9006.

1 reference

12 December 2020

MDM2 amplification and loss of heterozygosity at Rb and p53 genes: no simultaneous alterations in the oncogenesis of liposarcomas

1 reference

12 December 2020

The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website

1 reference

12 December 2020

10.1038/NRCLINONC.2012.48

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22473105%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

1 reference